Navigation Links
Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
Date:12/16/2013

y efficacy endpoint. In the study, patients treated with AVP-923 experienced levels of pain reduction commensurate with those observed in similar studies and the improvement in pain scores from baseline reached statistical significance; however, there was no difference between the treatment arms and placebo. Avanir stated that it plans to review the detailed data from the PRIME study in conjunction with previously generated data in diabetic peripheral neuropathic pain to determine next steps for the development of AVP-923 in neuropathic pain. The Full Research Report on Avanir Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/2ee8_AVNR

Sirona Dental Systems Inc. Research Report

On December 1, 2013, Sirona Dental Systems Inc. (Sirona) issued a press release providing highlights from the 2013 ADF dental exhibition in Paris, where the Company once again presented its full range of equipment for dental practices and labs. According to Sirona, its new intraoral camera APOLLO DI and the presentation of the continuous digital process chain at the Company stand interested many attendees. "The key topic at the ADF 2013 was definitely digital impression taking: It is and will remain the basis for a fast, simple, efficient workflow between the dental practice and the lab.  With the new APOLLO DI impression-taking system, Sirona offers dentists a highly economical entry into digital impression taking," explained Lionel Phelipot, General Manager of Sirona France. "The inexpensive APOLLO DI features easy handling, precise acquisition and the tried-and-tested Sirona Connect workflow The impression-taki
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
2. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013
3. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
4. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
5. Uroplasty Sets New Quarterly Revenue Record During Fiscal Second Quarter 2014
6. Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers
7. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
8. Zimmer Announces Quarterly Dividend for Third Quarter of 2013
9. Double Quarterly ExtraBucks is Back by Popular Demand: ExtraCare Members Can Earn Double This Fall at CVS/pharmacy
10. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
11. Quest Diagnostics Declares Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... HILL, Conn. , July 2, 2015 ... Chief Executive Officer announced that Tamas Feitel ... Feitel joins Numotion after a highly successful 18 ... finance leadership roles driving strategy, profitability, and productivity to ... His most recent position was Chief Financial Officer for ...
(Date:7/2/2015)... 2, 2015 The report "Silage ... Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), ... 2020", Silage Inoculants & Enzymes Market is expected to ... 4.0% from 2015 to 2020. Browse ... through 194 P ages and an ...
(Date:7/2/2015)... 2 de julio de 2015 BGI anunció ... de alto rendimiento en Hong Kong ... of Pathologists (CAP). La instalación de BGI en ... secuenciación de próxima generación que recibe la certificación CAP ... alto estándar en prácticas de laboratorio clínico. Junto con ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
... connectivity enabled by Unlimited Systems Interlink integration platform, Navigating ... cancer clinics easily meet many of the HITECH Act ... and money by reducing duplicate data entry, streamlining patient ... and reduced denials. Clinics can provide patients ...
... N.J., Oct. 18, 2011 Johnson & Johnson (NYSE: ... the third quarter of 2011, an increase of 6.8% as ... 2.6% and the positive impact of currency was 4.2%.  Domestic ... of 8.3% and a positive currency impact of 8.1%. ...
Cached Medicine Technology:Navigating Cancer and Unlimited Systems Partner to Provide Cancer Clinics With IT Interoperability to Attain HITECH Act Incentives 2Johnson & Johnson Reports 2011 Third-Quarter Results 2Johnson & Johnson Reports 2011 Third-Quarter Results 3Johnson & Johnson Reports 2011 Third-Quarter Results 4Johnson & Johnson Reports 2011 Third-Quarter Results 5Johnson & Johnson Reports 2011 Third-Quarter Results 6Johnson & Johnson Reports 2011 Third-Quarter Results 7Johnson & Johnson Reports 2011 Third-Quarter Results 8Johnson & Johnson Reports 2011 Third-Quarter Results 9Johnson & Johnson Reports 2011 Third-Quarter Results 10Johnson & Johnson Reports 2011 Third-Quarter Results 11Johnson & Johnson Reports 2011 Third-Quarter Results 12Johnson & Johnson Reports 2011 Third-Quarter Results 13Johnson & Johnson Reports 2011 Third-Quarter Results 14
(Date:7/3/2015)... ... July 03, 2015 , ... The ... June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. ... bicyclists and practical points of investigating these types of cases. , Each year, ...
(Date:7/3/2015)... ... 2015 , ... Jennifer Renee Hanes, DO is the new Medical Director of ... of independent freestanding emergency rooms in the United States. , “We are excited to ... said Executive Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. ...
(Date:7/3/2015)... Abilene, Texas (PRWEB) , ... July 03, 2015 , ... ... published a new article this week that he says will reveal biblical truth and ... article titled “Why Does Your Bible Say Don’t Have Sex”, immediately goes into the ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Mississippi. The premium frozen yogurt chain was listed as #22 on the Inc. 500 ... Avenue, New Albany, MS 38652, will have a grand opening event on July 4, ...
(Date:7/2/2015)... ... 2015 , ... Following the recent report by JAMA Internal Medicine ... overweight Americans, Samir Becic emphatically declared a war on obesity in the United States. ... said. "We must understand the magnitude of this discovery. For that reason, I am ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetfrog Opens First Location in Mississippi 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... 3 (HealthDay News) -- People with mental illness are ... serious cardiac event, a new study finds. One ... mental illness are 14 percent less likely to receive ... Those treatments included coronary artery bypass graft (bypass surgery) ...
... , THURSDAY, June 2 (HealthDay News) -- A class ... doesn,t boost the risk of cancer, as a recent ... drugs are known as angiotensin-receptor blockers (ARBs) and include ... and candesartan (Atacand). The determination comes from ...
... -- Poor sleep may be a factor in aggressive behavior ... who bully other kids are more likely to be sleepy ... the University of Michigan Medical School found that children with ... have sleep-disordered breathing problems or daytime sleepiness as other children ...
... investigates the challenges that pen and paper workarounds ... of electronic health records. Understanding these challenges may ... health IT. Focusing on referrals by primary ... specialists back to the referring physician, "Paper Persistence, ...
... American Society of Clinical Oncology (ASCO) Annual Meeting, cancer ... treating recurrent gliobastoma (GBM) has a favorable safety profile ... than the current median survival rate. Patients in ... University of California, San Francisco and Columbia University, were ...
... When earthquake, tsunami, tornado or flood strike, among the ... International Journal of Emergency Management , researchers in ... into account the age-related needs of adults with regards ... Robyn Tuohy and Christine Stephens of Massey University ...
Cached Medicine News:Health News:Mental Illness Linked to Greater Risk of Death After Heart Attack 2Health News:Popular Blood Pressure Meds Not Linked to Cancer, FDA Says 2Health News:Kids Who Bully Often Get Poor Sleep 2Health News:Paper and computer workarounds challenge but may improve health IT 2Health News:Paper and computer workarounds challenge but may improve health IT 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:Helping the aged during natural disasters 2
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... for the semi-quantitative determination of specific ... serum. The results of the anti-GBM.assay ... in the diagnosis of diseases associated ... including Goodpastures Syndrome. Levels of these ...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
Medicine Products: